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April 14, 2009:1339–42he Cardiorenal Syndrome
Classification Into 4 Groups?
he recent publication by Ronco et al. (1) provides a thorough
escription of the pathophysiology of the cardiorenal syndrome
CRS) and comes with a proposal for a new classification.
The innovative classification is based on the putative causative
athophysiological mechanism that underlies failure of the heart
nd kidneys. The classification focuses on 2 aspects of the process:
uration (acute onset vs. chronic disease), and the sequence of
vents (kidney failure first vs. heart failure first). For clinical
urposes, the distinction between acute and chronic CRS proposed
y the authors seems very useful: they propose a clinical syndrome
here acute heart failure (HF) leads to acute kidney injury (AKI)
type 1) and vice versa (AKI leading to acute HF; type 3). This
eems relevant, because both conditions have a different pathogen-
sis and require a different clinical approach. However, the
istinction between CRS type 2 (chronic HF leading to progres-
ive chronic kidney disease [CKD]) and CRS type 4 (CKD leading
o chronic HF and increased risk of cardiovascular events) is based
n the assumption that, also in advanced and chronic disease, 2
ifferent pathophysiological mechanisms can be distinguished.
In the paper by Bongartz et al. (2), we postulate a model of
chronic) cardiorenal interactions, with a quite different philoso-
hy. In that model, we have searched for the common denomina-
ors in heart and renal failure (i.e., for similar pathophysiological
nteractions in “heart-kidney” and “kidney-heart” failure). We have
een able to identify 4 cardiorenal connectors: inflammation, nitric
xide/reactive oxygen species balance, the sympathetic nervous
ystem, and the renin-angiotensin system. In our view these
onnectors are, in addition to the well-known hemodynamic
nteractions between heart and kidney, responsible for the strongly
rogressive nature of the disease process, because they evoke
ositive feedback mechanisms. Therefore, the sequence in which
he 2 conditions arise is not important.
Furthermore, we question the feasibility of the distinction
etween CRS type 2 and 4 in terms of diagnosis. In addition, both
roups are similar in terms of management, because they both
hould receive optimal interventions to block the interaction
etween the cardiorenal connectors, in addition to the specific
easures that apply to chronic HF and CKD.
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e are pleased to see that our recent paper (1) on cardiorenal
yndrome (CRS) has captured the attention of many investigators,
emonstrating the importance of this subject. We have received
everal positive comments on the structured classification/
efinition of the CRS that we have proposed. In their letter, Dr.
an der Putten and colleagues raise an important point about the
idirectional nature of chronic heart-kidney interactions and ques-
ion the wisdom of categorizing these into chronic “cardio-renal”
CRS 2) versus chronic “reno-cardiac” (CRS 4) syndromes. They
efer to a report by Bongartz et al. (2), who show that common
athophysiology leads to a chronic state of positive feedback
eading to progression of both heart and kidney disease. Indeed,
his article is a “must read” for anyone with an interest in this
isorder, because it highlights a number of important mechanisms
hat perpetuate and amplify structural and functional derangement,
eyond simple hemodynamics.
We agree with Dr. van der Putten and colleagues that the
equence in which chronic heart-kidney conditions arise might not
e of paramount clinical importance, because management strat-
gies need to address interruption of these positive feedback loops
here possible. However, we also posit that a categorization
cheme serves an important role in terms of designing epidemio-
ogical studies, identifying target populations for intervention,
eveloping targeted diagnostic tools, studying the prevention and
anagement of the syndromes, and promoting effective commu-
ication and collaboration among researchers and clinicians from
iffering disciplines. In response to these issues, a consensus
onference was recently held in Venice, Italy in September 2008
nder the auspices of the Acute Dialysis Quality Initiative
ADQI), bringing together key opinion leaders and experts in the
elds of nephrology, critical care, cardiac surgery, cardiology, and
pidemiology. At this conference, a consensus definition and
lassification system for the CRS was reached with the 5 subtypes
roposed in our review. The ADQI working group recognized that
any patients might populate or move between subtypes during
he course of their disease, and indeed it might not always be
ossible to categorize a patient as CRS type 2 or 4. However, the
lassification is a work in progress, and feedback from interested
roups such as Dr. van der Putten and colleagues will be important
or future refinements and iterations.
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ost-Exercise Release
f Cardiac Troponins
ost-exercise release of cardiac troponin (cTn)T and cTnI has
een previously reported after prolonged strenuous exercise (1). Up
o now, it has been unclear whether post-exercise release of cTn
epresents necrosis of cardiac myocytes and thus irreversible
amage or a transient and reversible change in membrane perme-
bility of the myocyte (1). Similarly, whether the substrate for
ost-exercise release of cTn is physiologic or pathologic has not
een determined (1).
Middleton et al. (2) examined the kinetics of cTnT during and
fter completion of a marathon on a motorized treadmill. They
uggest that the consistent elevation and pattern of cTnT observed
n all participants during and after exercise likely reflects a
hysiologic as opposed to pathologic substrate. It seems unlikely
hat minor elevations in cTnT subsequent to endurance exercise
re due to myocardial necrosis (2). Rather, it is possible that
ost-exercise cTn release represents reversible cardiomyocyte mem-
rane damage that might reflect part of a remodeling process (2).
To test the effects of reversible myocardial ischemia, Kurz et al.
3) used a pre-commercial high-sensitivity cardiac troponin T
hsTnT) assay with a 5-fold lower detection limit than the
tandard assay. Single-photon emission computed tomography was
erformed to objectively document transient reversible ischemia.
he finding that hsTnT does not increase after reversible myocar-
ial ischemia supports the experimental results of Fishbein et al.
4), demonstrating that troponin release was restricted to irrevers-
ble myocyte necrosis. Moreover, intact cTnI and degradation
roducts were detectable by Western blot-direct serum assay
WB-DSA) in patients with acute ST-segment elevation myocar-
ial infarction (5). Metabolic inhibition of cardiomyocytes induces
arallel release of intact cTnT and cTnI and their degradation
roducts, starting only after onset of irreversible cardiomyocyte
amage (6). By contrast a recent study demonstrates that viable
ardiomyocytes release cTnI as an intact protein by a stretch-
elated mechanism mediated by integrins (7). Integrin stimulation
n cardiomyocytes does not result in degradation of cTnI into its
ragments (7). Accordingly, if post-exercise release of cTn repre-
ents reversible cardiomyocyte membrane damage, it is due to a
tretch-related mechanism (7) as opposed to metabolic stress or
schemia (3,4,6). However, it has been previously demonstrated
hat no relationship exists between post-exercise cTn release and a
tretch-related mechanism (8).
Therefore, it is possible that release of cTn represents irrevers-
ble damage that has been proposed either as pathognomic of
ardiac necrosis or might reflect part of a remodeling process
physiologic substrate) (1,9). To further understand exercise-
nduced cTn release, future work should use WB-DSA (5) to Hemonstrate degradation products representing irreversible cardi-
myocyte damage (3,4,6,7).
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e thank Drs. Koller and Schobersberger for their interest in our
tudy (1). The mechanism of release of cardiac troponin (cTn) in
pparently healthy individuals remains unclear (2). Our data
emonstrate that cTn might be released in all individuals after
rolonged exercise and have been confirmed by others (2). Recent
tudies using highly sensitive developmental assays demonstrate a
ormal distribution of cTn in apparently healthy populations (2,3).
herefore, it is likely that post-exercise release of cTn is due to a
hysiologic as opposed to a pathologic substrate. Conversely,
levations of cTnT above the 99th percentile of currently available
ommercial assays confer poor prognosis in general clinical popu-
ations (4).
Koller and Schobersberger suggest, on the basis of the work of
essel et al. (5), a potential physiologic mechanism responsible for
ost-exercise cTn release. Ventricular stretch induced by pro-
onged exercise might stimulate integrins located in the cellular
embrane that link the cytoskeleton to the extracellular matrix.
ntegrins could facilitate transport of the small (3% to 8%)
ytosolic fraction of cTn out of healthy cardiomyocytes (6).
owever, the careful interpretation of Western blotting performed
